France
Affluent Medical, a French medtech startup founded in 2011, aims to become a leading force in the European structural heart disease and urology sectors. The company is focused on developing innovative minimally invasive implants to restore essential physiological functions in these areas. Its products include Kardiozis to prevent aortic aneurysm leaks and recurrence, Kalios and Epygon for more physiological surgical treatments of the mitral heart valve, and Artus, the first electronically adjustable artificial sphincter for urinary incontinence. These advancements are designed to offer medical devices that better respect the human body's physiology and are aimed at reducing the risks of early or late disease recurrence.
At present, Affluent Medical's three innovative prostheses and technology are in preclinical or clinical phases. The startup recently secured a €8.54M Post-IPO Equity investment on July 15, 2024, from Edwards Lifesciences, showcasing confidence from a prominent player in the industry.
With its focus on addressing unmet needs in structural heart disease, vascular therapy, and urology, Affluent Medical presents an intriguing investment opportunity in the biotechnology, health care, and medical devices sectors. The startup's innovative approach and recent investment reveal promise for its growth and impact in these critical healthcare domains, making it a compelling venture for potential investors.
